Because MR has previously been used to predict the impact of current and proposed ApoB-lowering therapies on CAD risk, we sought to explore the effect of these treatments on PAD risk.16 We first performed polygenic and gene-based MR analyses to determine whether ApoB-associated genetic variants located within/near genes encoding these therapeutic targets were associated with risk of PAD. Here, APOB is linked to coronary artery disorder.